Developing good scientific publishing practices: One pharmaceutical companys perspective

Current Medical Research and Opinion

Volumn 26, Issue 6, 2010, Pages 1249-1254

  Dowsett, Sherie A ^a   Van Campen, Luann E ^a   Bednar, Lisa A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Authorship; Conflict of interest; Ghostwriting; Guest authorship; Pharmaceutical industry; Scientific publishing

Indexed keywords

ACCESS TO INFORMATION; BUSINESS ETHICS; CONFLICT OF INTEREST; DRUG INDUSTRY; MEDICAL RESEARCH; NOTE; POLICY; PUBLISHING; SCIENTIFIC LITERATURE; WRITING;

AUTHORSHIP; BIOMEDICAL RESEARCH; CONFLICT OF INTEREST; DRUG INDUSTRY; EDITORIAL POLICIES; JOURNALISM; PUBLICATION BIAS;

EID: 77952538757     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007991003748880     Document Type: Note

References (20)

1. Science and Engineering Indicators, 2008. Available at: http://www.nsf.gov/statistics/seind10/[Last accessed March 15, 2010]
2. Moses H, Dorsey ER, Matheson DHM, Thier SO. Financial Anatomy of Biomedical Research. JAMA 2005;294:1333-1342
3. Cassell GH. Interactions of the public and private sectors in drug development: boundaries to protect scientific values while preserving innovation. Cleve Clin J Med 2007;74(Suppl 2):S45-8
4. Campbell EG, Koshki G, Blumenthal D. The triple helix; university, government and industry relationships in the life sciences. Working policy paper of the AEI-Brookings Joint Center on Regulatory Studies; May 27, 2004. Available at: www.kauffman.org/pdf/triple-helix-061104.pdf [Last accessed December 3, 2009]
5. Lichtenberg: NBER Working Paper No. 9754* Issued in June 2003. Available at: http://www.nber.org/papers/w9754 [Last accessed December 3, 2009]
6. Fontanarosa PB, Flanagin A, DeAngelis CD. Reporting conflicts of interest, financial aspects of research, and role of sponsors in funded studies. JAMA 2005;294:110-111
7. Ross JS, Hill KP, Egilman DS, et al. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA 2008;299:1800-1812
8. Singer N. Medical Papers by Ghostwriters Pushed Therapy. New York Times August 5, 2009
9. Rennie D. Thyroid storm. JAMA 1997;277:1238-1243
10. Kondro W, Sibbald B. Drug company experts advised staff to withhold data about SSRI use in children. CMAJ 2004;170:783
11. Als-Nielsen D, Chen W, Gluud C, et al. Association of funding and conclusion in randomized drug trials. A reflection of treatment effect or adverse events? JAMA 2003;290:921-928
12. Lopatto E, Feeley J, Cronin M. Lilly 'ghostwrote' articles to market drug, files say (Update2). Available at: Fiskhttp://www.bloomberg.com/apps/news? pid-20601087&sid-a6yFu-t9NyTY [Last accessed December 3, 2009]
13. Accreditation Council for Continuing Medical Education. Available at: http://www.accme.org/index.cfm/fa/faq.detail/category-id/667b72cf-6277-4317- 99f9-1e476b621e76.cfm [Last accessed December 3, 2009]
14. Eli Lilly and Company. Principles of Medical Research. Available at: http://www.lilly.com/about/compliance/practices/[Last accessed December 3, 2009]
15. Institute of Medicine. Conflict of Interest in Medical Research, Education, and Practice. Washington, DC: National Academies Press, 2009
16. Last JM. A Dictionary of Epidemiology. New York, NY: Oxford University Press, 2001
17. Biagioli M. The instability of authorship: credit and responsibility in contemporary biomedicine. FASEB J 1998;12:3-16
18. Singer N. Senator moves to block medical ghostwriting. New York Times, August 18, 2009
19. International Council of Journal Medical Editors Uniform requirements. Available at: http://www.icmje.org/[Last accessed December 3, 2009]
20. Burnham J. The evolution of editorial peer review. JAMA 1990;263: 1323-1329